

11 South Meridian Street
Indianapolis, Indiana 46204
(317) 236-1313
(317) 231-7433 Fax

IN THE UNITED STATES PATENT OFFICE

AP20 Rec'd PCT/PTO 22 JUN 2006

Earliest Priority Date: 23 December 2003 (23.12.03)

International Serial No.: PCT/US2004/043145

U.S. Serial No.: Unknown

Invention: CO-ADMINISTRATION OF
DOPAMINE-RECEPTOR BINDING
COMPOUNDS

Applicant: FERNANDES, Prabhavathi B.;
MAILMAN, Richard Bernard;
NICHOLS, David Earl;
POSTLETHWAIT, Robert Niel

International Filing Date: 22 December 2004 (22.12.04)


Attorney Docket: 30152-200316

Certificate Under 37 CFR 1.10

Express Mail No.: EV 417055260 US

Date of Mailing: 22 June 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.


(Signature)Mary Jean Eskridge

(Typed or Printed Name of Person Mailing Paper or Fee)

INFORMATION DISCLOSURE STATEMENT

Attn: DO/EO/US
Mail Stop: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

This statement is filed in the application identified above pursuant to 37 C.F.R. § 1.56. In accordance with 37 C.F.R. § 1.98(a)(2), no copies of the cited U.S. references are provided. A copy of each of the other references is provided for review by the Examiner.


No representation is intended that a complete search has been made of the prior art or that no better art references than those listed below are available. The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

10/584019

AP20 Rec'd PCT/PTO 22 JUN 2006

Please charge any fees that might be due in connection with this Information Disclosure Statement to our Deposit Account No. 10-0435, using our reference number 30152-200316. A duplicate copy of this authorization is enclosed for that purpose.

Respectfully submitted,



Kevin L. McLAREN

Atty. Reg. No. 48351

Attorney for Applicants

KLM/mje/817119v1
Indianapolis, Indiana 46204
(317) 231-7776

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

30152-200316

SERIAL No.

10/584019

APPLICANT
FBI LABORATORY
FILING DATE

December 22, 2004 (IFD)

UNKNOWN

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA	5,047,536	09/10/1991	NICHOLS, David E.			
	AB	5,420,134	05/30/1995	NICHOLS, David E. et al.			
	AC	5,597,832	01/28/1997	MICHAELIDES, Michael R. et al.			
	AD	5,744,476	04/28/1998	LOCKE, Kenneth Walter et al.			
	AE	6,147,072	11/14/2000	BYMASTER, Franklin P., et al.			
	AF	6,413,977 B1	07/02/2002	NICHOLS, David E. et al.			
	AG	6,420,351 B1	07/16/2002	TSAI, Guochuan; COYLE, Joseph			
	AH	6,645,971 B1	11/11/2003	SIT, Sing-Yuen et al.			
	AI	6,916,823 B2	07/12/2005	MAILMAN, Richard B., et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	AJ						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	ARNSTEN, A.F.T. et al.; "Dopamine D ₁ receptor mechanisms in the cognitive performance of young adult and aged monkeys," Psychopharmacology, 1994; 116: pp. 143-151
	AL	CASTNER, Stacy A. et al.; "Reversal of Antipsychotic-Induced Working Memory Deficits by Short-Term Dopamine D ₁ Receptor Stimulation," Science; 17 March 2000, Vol. 287, pp. 2020-2022
	AM	LEWIS, Mechelle M. et al.; "Homologous Desensitization of the D _{1A} Dopamine Receptor: Efficacy in Causing Desensitization Dissociates from Both Receptor Occupancy and Functional Potency," Pharmacology, July 1998, Vol. 286, Issue 1, pp. 345-353
	AN	LIDOW, Michael S. et al.; "Down-Regulation of the D ₁ and D ₅ Dopamine Receptors in the Primate Prefrontal Cortex by Chronic Treatment with Antipsychotic Drugs," Pharmacology, 1997, Vol. 281, Issue 1, pp. 597-603
	AO	NICHOLS, David E.; "The Development of Novel Dopamine Agonists," ACS Symposium Series 224, 1983, Comstock, M. Joan, Ed., Based on a symposium sponsored by the ACS Division of Medicinal Chemistry at the 184th Meeting of the American Chemical Society, Kansas City, MO, September 12-17, 1982, American Chemical Society
	AP	SCHNEIDER, J.S. et al.; "Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys," Brain Research, 1994, 663; pp. 140-144
	AQ	SMITH, Hilary P. et al.; Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D ₂ post-synaptic receptor agonist," European Journal of Pharmacology, 1997, 323, pp. 27-36
	AR	WATTS, V. J. et al. "Hexahydrobenzo[a]phenanthridinines: novel dopamine D ₃ receptor ligands," European Journal of Pharmacology, August 3, 1993; 239, pp. 271-273

Examiner _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.